Ionis Posts Surprise Q2 Profit, Double Revenues On Stronger Sales From Newly Approved Genetic Disease Drug Ionis reports surprise Q2 profit, raises 2025 forecast after strong Tryngolza launch and royalty gains push revenue past expectations.
IONIS PHARMACEUTICALS INC (NASDAQ:IONS) - A Strong Technical Setup Worth Watching IONIS Pharmaceuticals (
NASDAQ:IONS ) shows strong technicals with an 8/10 rating and a high-quality setup pattern, making it a breakout candidate for traders.
Biogen-Ionis Partnered Drug Shows Benefit In Children With Spinal Muscular Atrophy Previously Treated With Novartis' Zolgensma Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in neurodegeneration markers after one-year dosing.
Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug? Biogen is hoping to top its own spinal muscular atrophy treatment, Spinraza, with a next-generation version.
Ionis Pharmaceuticals Narrows Q1 Loss, Lifts Revenue Forecast While Drug Sales Surge Ionis Pharmaceuticals beat Q1 earnings and revenue estimates, raising its 2025 outlook, and reported strong sales from new and existing drug products.
Drugmaker Ionis Pharmaceuticals Garners Analyst Praise For 'Pipeline Depth' HC Wainwright initiates Ionis with Buy rating and $45 target, citing strong pipeline, solid revenue, and key clinical milestones ahead.
Competitive Analysis In The ATTR-CM Field Precision medicine was proved in the ATTR-CM field. We think acoramidis is a more potent TTR stabilizer and that it will attract first-line patients. Tafamidis, acoramidis and vutrisiran will share the ATTR-CM market in the next 3 years.
Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal Ionis grants Ono global rights to sapablursen for polycythemia vera in a deal worth up to $940M, including milestones and royalties on future sales.
Ionis Pharma Beats Expectations for Q4 The biotech outperformed expectations with better-than-expected revenue and a smaller-than-expected loss.
Ionis Pharmaceuticals Q4 Revenue Growth Exceeds Guidance, Forecasts Over $600 Million In 2025 Sales Ionis Pharmaceuticals posted a smaller-than-expected Q4 loss and exceeded revenue estimates. The company projects 2025 revenue of over $600 million.
